Skip to main content
EXACT Therapeutics AS logo

EXACT Therapeutics AS — Investor Relations & Filings

Ticker · EXTX ISIN · NO0010852213 LEI · 2138006ZE5JAL39AGD55 OL Manufacturing
Open in API
Filings indexed 233 across all filing types
Latest filing 2023-05-30 Regulatory Filings
Country NO Norway
Listing OL EXTX

About EXACT Therapeutics AS

https://www.exact-tx.com/

EXACT Therapeutics AS is a clinical-stage biopharmaceutical company developing its proprietary technology platform, Acoustic Cluster Therapy (ACT®), for targeted therapeutic enhancement. The ACT® platform uses ultrasound to amplify the effect of co-administered drugs, with a primary focus on oncology. Its biomechanical mode of action increases the local uptake of therapeutics from blood vessels into the surrounding tissue, including across the blood-brain barrier, without requiring drug reformulation. This non-invasive technology is designed to be compatible with standard ultrasound systems. The company's pipeline includes the ENACT study, a Phase 2 trial evaluating ACT® in patients with locally advanced pancreatic cancer, following the completion of the ACTIVATE Phase 1 study in patients with liver metastases.

Recent filings

Filing Released Lang Actions
EXACT Therapeutics Announces Granted Patent in United Kingdom for Acoustic Cluster Therapy (ACT®)
Regulatory Filings Classification · 95% confidence The document is a press release titled "EXACT Therapeutics Announces Granted Patent in United Kingdom for Acoustic Cluster Therapy (ACT®)". It explicitly announces the issuance of a UK Patent (GB2595513) related to their technology. This type of announcement, concerning intellectual property rights (patents), does not fit neatly into the primary financial reporting categories (10-K, IR, ER, etc.). It is a specific corporate update regarding legal/IP assets. Since there is no specific code for 'Patent Grant Announcement', and it is a formal announcement of a legal/IP development, it falls best under the general 'Regulatory Filings' category (RNS) as a miscellaneous, non-financial, regulatory-adjacent announcement, or potentially 'LTR' (Legal Proceedings Report) if patents were viewed strictly as legal matters, but RNS is a better fit for general corporate news filings that aren't standard financial reports or insider trades. Given the options, RNS serves as the most appropriate catch-all for significant, non-financial corporate news like patent grants.
2023-05-30 English
EXACT Therapeutics AS announces the publication of the 2022 Annual Report
Annual Report Classification · 100% confidence The document is explicitly titled 'Annual Report – 2022' and contains comprehensive sections including a letter from the CEO, operational review, financial review, corporate governance, and full financial statements for both the Group and the Parent company. It meets the criteria for an Annual Report (10-K equivalent for this jurisdiction) as it provides a full yearly overview of company activity and financial performance. FY 2022
2023-04-21 English
EXACT Therapeutics AS announces the publication of the 2022 Annual Report
Report Publication Announcement Classification · 100% confidence The document explicitly states: 'EXACT Therapeutics AS announces the publication of the 2022 Annual Report' and provides contact information and a link to the report. The document length is very short (1406 characters). According to Rule #2 (The 'MENU VS MEAL' Rule), a short announcement stating that a report has been published, rather than containing the full report content, should be classified as a Report Publication Announcement (RPA).
2023-04-21 English
EXACT Therapeutics presents encouraging clinical case report data at Science & Technology Event
Earnings Release Classification · 95% confidence The document is a press release dated March 28, 2023, announcing that EXACT Therapeutics presented clinical case report data at a Science & Technology Event. It details encouraging results from a Phase I trial (ACTIVATE) regarding their Acoustic Cluster Therapy (ACT®) combined with chemotherapy. This content focuses on presenting preliminary clinical findings and updates on ongoing research/trials, which is characteristic of an Earnings Release (ER) or a general Investor Presentation (IP) update, but since it is a formal announcement of results/data presentation rather than a full quarterly report (IR) or a formal presentation deck (IP), it fits best as an Earnings Release (ER) which often includes key operational and clinical updates, or potentially a Regulatory Filing (RNS) if it were a mandatory disclosure. Given the focus on presenting 'encouraging clinical case report data' and updates on the trial progress, it functions as an announcement of recent performance/data milestones. It is not a full financial report (10-K, IR), a transcript (CT), or a specific governance/director filing. ER is the most appropriate fit for a press release highlighting recent operational/clinical results. Q1 2023
2023-03-28 English
EXACT Therapeutics presents encouraging clinical case report data at Science & Technology Event
Investor Presentation Classification · 95% confidence The document is a press release dated March 28, 2023, announcing that EXACT Therapeutics presented clinical case report data from its Phase I ACTIVATE trial at a Science & Technology Event. It details preliminary positive results regarding safety, tolerability, and tumor response enhancement when combining Acoustic Cluster Therapy (ACT) with chemotherapy. This type of announcement, focusing on clinical trial updates, scientific presentations, and general company news outside of mandatory financial filings (like 10-K or ER), most closely aligns with a general Investor Presentation (IP) or a broad Regulatory Filing (RNS). Since it is a detailed presentation of clinical data and future trial plans aimed at investors, 'Investor Presentation' (IP) is a strong candidate, although it is structured as a press release. However, given the content is a summary of data presented at an event, and not the full presentation document itself, it functions as an announcement of scientific progress. If the content were a formal, structured presentation deck, IP would be perfect. As a news release summarizing scientific findings and trial progress, it fits well under the general 'Regulatory Filings' (RNS) category if a more specific category like 'IP' is reserved for the actual slide deck. Given the context of presenting clinical data and trial progress, it is a form of investor communication. Comparing the options, it is not a formal financial report (10-K, IR, ER), nor a management change (MANG), nor a dividend notice (DIV). It is an announcement of scientific/clinical progress. Since 'Investor Presentation' (IP) is defined as a 'Detailed presentation for investors focusing on financials, strategy, and market position,' and this document details clinical strategy and results, IP is the most specific fit for the *information type*, even if the *format* is a press release. If the document were purely a notice that a presentation occurred, RPA would fit, but this document contains substantial content from the presentation. I will classify it as IP based on content focus.
2023-03-28 English
Exact Therapeutics receives regulatory approval to reopen the ACTIVATE clinical trial
Regulatory Filings Classification · 100% confidence The document is a press release dated February 2, 2023, announcing that Exact Therapeutics received regulatory approval from the UK MHRA to reopen its ACTIVATE clinical trial. This announcement concerns a specific regulatory event (approval to proceed with a trial) and is not a comprehensive financial report (like 10-K or IR), an earnings release (ER), or a management discussion (MDA). It details an update on a legal/regulatory matter concerning the company's operations and clinical status. While it relates to regulatory interaction, it is most specifically an update on a significant legal/regulatory proceeding or action affecting the company's operations, which aligns best with the 'Legal Proceedings Report' (LTR) category, as it discusses regulatory actions and trial amendments/approvals. Given the context of regulatory interaction regarding a clinical trial, LTR is the most fitting specific category, although RNS could also apply as a general regulatory announcement. Since it details the outcome of a regulatory request/issue, LTR is preferred over the general RNS fallback.
2023-02-02 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.